UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

Clinical pharmacokinetics, 2016-06, Vol.55 (6), p.673-696

2016

Volltextzugriff (PDF)

Animal versus human oral drug bioavailability: Do they correlate?

European journal of pharmaceutical sciences, 2014-06, Vol.57 (100), p.280-291

2014

Volltextzugriff (PDF)

Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine

Pharmaceutical research, 2015-01, Vol.32 (1), p.74-90

2015

Volltextzugriff (PDF)

Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination

The AAPS journal, 2016-05, Vol.18 (3), p.589-604

2016

Volltextzugriff (PDF)

Quantifying gut wall metabolism: methodology matters

Biopharmaceutics & drug disposition, 2017-03, Vol.38 (2), p.155-160

2017

Volltextzugriff (PDF)

The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data

Pharmaceutical research, 2014-03, Vol.31 (3), p.720-730

2014

Volltextzugriff (PDF)

PBPK models for the prediction of in vivo performance of oral dosage forms

European journal of pharmaceutical sciences, 2014-06, Vol.57 (SI), p.300-321

2014

Volltextzugriff (PDF)

Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors

Biopharmaceutics & drug disposition, 2017-04, Vol.38 (3), p.187-208

2017

Volltextzugriff (PDF)

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects

British journal of clinical pharmacology, 2021-07, Vol.87 (7), p.2711-2722

2021

Volltextzugriff (PDF)

Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations

The AAPS journal, 2019-05, Vol.21 (3), p.42-42, Article 42

2019

Volltextzugriff (PDF)

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

CPT: pharmacometrics and systems pharmacology, 2022-07, Vol.11 (7), p.822-832

2022

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study

Pharmaceutics, 2023-07, Vol.15 (7), p.1922

2023

Volltextzugriff (PDF)

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs

CPT: pharmacometrics and systems pharmacology, 2021-11, Vol.10 (11), p.1382-1395

2021

Volltextzugriff (PDF)

P214 - Investigating the impact of enzyme correlations on inter-individual variability in pharmacokinetics and drug-drug interactions

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S87-S87

2020

Volltextzugriff (PDF)

Assessing the OATP1B1- and OATP1B3-mediated drug–drug interaction potential of mammalian target of rapamycin (MTOR) inhibitor everolimus

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S48-S48

2018

Volltextzugriff (PDF)

Exploring the impact of ethnicity on drug pharmacokinetics using PBPK models: a case study with lansoprazole in Japanese subjects

British journal of clinical pharmacology, 2024-01

2024

Volltextzugriff (PDF)

Integration of cyp and non-cyp hepatic abundance changes in PBPK modelling of renal impairment (RI) populations

Drug metabolism and pharmacokinetics, 2024-04, Vol.55, p.100971, Article 100971

2024

Volltextzugriff (PDF)

Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport

Journal of pharmaceutical sciences, 2017-08, Vol.106 (8), p.2123-2135

2017

Volltextzugriff (PDF)

Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis

Clinical pharmacology and therapeutics, 2023-12, Vol.114 (6), p.1264-1273

2023

Volltextzugriff (PDF)

Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models

Journal of pharmaceutical sciences, 2021-01, Vol.110 (1), p.314-324

2021

Volltextzugriff (PDF)

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model

Drug metabolism and disposition, 2016-06, Vol.44 (6), p.821-832

2016

Volltextzugriff (PDF)

A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients

European journal of pharmaceutical sciences, 2020-07, Vol.150, p.105355, Article 105355

2020

Volltextzugriff (PDF)

Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions

Journal of pharmaceutical sciences, 2019-10, Vol.108 (10), p.3443-3456

2019

Volltextzugriff (PDF)

Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin

The AAPS journal, 2018-05, Vol.20 (3), p.47-47, Article 47

2018

Volltextzugriff (PDF)

Pre-incubation with everolimus and sirolimus reduces organic anion transporting polypeptide (OATP)1B1- and 1B3-mediated transport independently of mTOR kinase inhibition: implication in assessing OATP1B1- and OATP1B3-mediated drug-drug interactions

Journal of pharmaceutical sciences, 2019-04, Vol.108 (10), p.3443-3456

2019

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(32)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(24)
Science & Technology
(24)
Pharmacology & Pharmacy
(22)
Humans
(18)
Models, Biological
(12)
Pharmacokinetics
(12)
Animals
(9)
Drug Interactions
(9)
Pharmacology/toxicology
(6)
Administration, Oral
(5)
Biochemistry
(5)
Biomedical And Life Sciences
(5)
Biomedicine
(5)
Chemistry
(5)
Chemistry, Multidisciplinary
(5)
Pharmacy
(5)
Physical Sciences
(5)
Computer Simulation
(4)
Cytochrome P-450 Enzyme System - Metabolism
(4)
Drug Development
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models

Animal versus human oral drug bioavailability: Do they correlate?

Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine

Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination

Quantifying gut wall metabolism: methodology matters

The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data

PBPK models for the prediction of in vivo performance of oral dosage forms

Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects

Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs

P214 - Investigating the impact of enzyme correlations on inter-individual variability in pharmacokinetics and drug-drug interactions

Assessing the OATP1B1- and OATP1B3-mediated drug–drug interaction potential of mammalian target of rapamycin (MTOR) inhibitor everolimus

Exploring the impact of ethnicity on drug pharmacokinetics using PBPK models: a case study with lansoprazole in Japanese subjects

Integration of cyp and non-cyp hepatic abundance changes in PBPK modelling of renal impairment (RI) populations

Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport

Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis

Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model

A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients

Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions

Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin

Pre-incubation with everolimus and sirolimus reduces organic anion transporting polypeptide (OATP)1B1- and 1B3-mediated transport independently of mTOR kinase inhibition: implication in assessing OATP1B1- and OATP1B3-mediated drug-drug interactions

Suchergebnisse filtern